AxoGen AXGN 深 沪
已收盘 09-26 16:00:00 美东时间
17.16
+0.240
+1.42%
华盛通- 最 高17.26
- 今 开16.92
- 成交量 91.81万股
- 最 低 16.6804
- 昨 收 16.92
- 总市值 7.90亿
- 52周最高 21.00
- 市盈率 静 --
- 换手率 2.00%
- 52周最低 9.215
- 委 比 -76.16%
- 总股本 4601.26万
- 历史最高 56.85
- 量 比 1.14
- 振 幅 3.43%
- 历史最低 1.10
- 每 手 1
- 风险率 2.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Axogen, Inc. announced that its management will participate in four upcoming investor conferences in September 2025. The company, a global leader in peripheral nerve regeneration solutions, will engage in fireside chats and 1x1 investor meetings across key healthcare conferences in NYC and Boston. Axogen is focused on developing innovative surgical solutions to restore peripheral nerve function, offering products like Avance® Nerve Graft and Axog...
08-27 12:00
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
U.S. stocks were mixed, with the Dow Jones index falling more than 200 points o...
08-26 00:02
FDA Extends Review for AxoGen’s Avance Nerve Graft
AxoGen ( ($AXGN) ) has issued an update. On August 22, 2025, Axogen, Inc. annou...
08-25 18:58
Axogen Receives FDA Major Amendment Designation, Delaying Avance Nerve Graft Decision
Axogen, Inc. (NASDAQ:AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance®
08-25 18:46
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
The U.S. Food and Drug Administration (FDA) has extended the PDUFA goal date for Axogen, Inc.'s Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025. This change follows the submission of a Major Amendment to the BLA, which included new manufacturing and facility data. The FDA also anticipates providing feedback on product labeling in November 2025.
08-25 10:40
Axogen shares are trading higher after the company reported better-than-expected Q2 financial results.
Axogen shares are trading higher after the company reported better-than-expecte...
08-05 20:30
Axogen Narrows FY2025 Sales Guidance from $215.439M-$219.185M to $219.000M vs $216.463M Est
Axogen (NASDAQ:AXGN) narrows FY2025 sales outlook from $215.439 million-$219.185 million to $219.000 million vs $216.463 million estimate.
08-05 19:04
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Axogen gains on report of takeover interest
Axogen (NASDAQ:AXGN) rose 3.8% after a report that the company is exploring a possible sale after receiving takeover interest. The company received interest from a strategic buyer for $18 a share, acc...
07-30 01:29
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in peripheral nerve regeneration technologies, announced that its management will host one-on-one investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. Axogen specializes in innovative surgical solutions to restore peripheral nerve function and improve patients' quality of life. Their product portfolio includes advanced nerve repair technologies like Avance Nerve ...
07-29 20:10
